Please login to the form below

Not currently logged in
Email:
Password:

Approval for S-A's prostate cancer drug

Sanofi-aventis has been granted EU approval to market its advanced prostate cancer treatment, Jevtana

Sanofi-aventis (S-A) has been granted EU approval to market its advanced prostate cancer treatment, Jevtana (cabazitaxel).

The drug has been approved in combination with prednisone/prednisolone in patients with metastatic hormone-refractory prostate cancer (mHRPC) who have previously undergone a docetaxel-containing regimen.

Jevtana had previously been given a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) – the European Medicines Agency's (EMA) committee to offer advice on medicines to be used in humans.

It has also been approved for use in the US by the Food and Drug Administration (FDA) in 2010.

Jevtana has shown positive results in the phase III TROPIC study, which involved 755 patients with mHRPC previously treated with a docetaxel-containing treatment regimen.

It found the median survival of patients receiving Jevtana was 15.1 months. This was 2.4 months longer than patients receiving mitoxantrone, a current chemotherapy treatment for prostate cancer.

21st March 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....